Scribe Therapeutics
Scribe is enabling the creation of genetic medicines through its CRISPR by Design™ approach to genetic modification.
Work at Scribe Therapeutics in HR or recruiting? Claim this page
Headcount trend
Scribe Therapeutics went from 128 employees in Oct 2024 to 86 in Sep 2026. Apr to Sep 2026: 3 people joined, 7 left.
Funding rounds
| Date | Round | Money raised | No. | Investors |
|---|---|---|---|---|
| Mar 2021 | Series B | $100M | 8 | |
| Oct 2020 | Series A | $20M | 1 | |
| Nov 2017 | Seed | – | – | – |
Org structure
Headcount by department
H-1B sponsorship
The department split adds up all the years listed above. FY2025 alone: 2 filings.
Peer reviews
Worked with someone at Scribe Therapeutics?
Anonymous peer reviews on OffTheRecord
Similar companies
Scribe Therapeutics FAQ
How many employees does Scribe Therapeutics have?
Scribe Therapeutics has about 86 employees, down 2.3% over the 3 months to Sep 2026.
Does Scribe Therapeutics sponsor H1B visas?
Yes. Scribe Therapeutics filed 2 H1B (LCA) applications in FY2025, according to the latest U.S. Department of Labor disclosures. Most of them were for Engineering roles.
What is Scribe Therapeutics's revenue per employee?
Scribe Therapeutics makes about $29K in revenue per employee, based on $2.5M annual revenue and 86 employees.
How much funding has Scribe Therapeutics raised?
Scribe Therapeutics has raised $120M in total funding; its latest round was Series B in Mar 2021.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.